Overview

A Study of NIDO-361 in Patients With SBMA

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).

Phase:

PHASE2

Details

Lead Sponsor:

Nido Biosciences, Inc.